[go: up one dir, main page]

CY1110176T1 - Combinations For HCV Therapy - Google Patents

Combinations For HCV Therapy

Info

Publication number
CY1110176T1
CY1110176T1 CY20091100274T CY091100274T CY1110176T1 CY 1110176 T1 CY1110176 T1 CY 1110176T1 CY 20091100274 T CY20091100274 T CY 20091100274T CY 091100274 T CY091100274 T CY 091100274T CY 1110176 T1 CY1110176 T1 CY 1110176T1
Authority
CY
Cyprus
Prior art keywords
hepatitis
relates
combinations
virus
combination
Prior art date
Application number
CY20091100274T
Other languages
Greek (el)
Inventor
Roger D Tung
Gurudatt Chandorkar
Robert B Perni
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of CY1110176T1 publication Critical patent/CY1110176T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to co-administering a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The combination acts by interfering with the life cycle of the hepatitis C virus and is therefore useful as an antiviral therapy. As such, the combination may be used for treating or preventing Hepatitis C infections in patients. The invention also relates to compositions comprising the combination of inhibitors. The invention also relates to kits and pharmaceutical packs comprising a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The invention also relates to processes for preparing these compositions, combinations, kits, and packs.
CY20091100274T 2003-10-27 2009-03-10 Combinations For HCV Therapy CY1110176T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51485303P 2003-10-27 2003-10-27
EP04810032A EP1677827B1 (en) 2003-10-27 2004-10-27 Combinations for hcv treatment

Publications (1)

Publication Number Publication Date
CY1110176T1 true CY1110176T1 (en) 2015-01-14

Family

ID=34549356

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100274T CY1110176T1 (en) 2003-10-27 2009-03-10 Combinations For HCV Therapy

Country Status (22)

Country Link
US (3) US20060003942A1 (en)
EP (1) EP1677827B1 (en)
JP (1) JP2007509950A (en)
KR (1) KR20060120162A (en)
CN (1) CN1893978A (en)
AT (1) ATE416789T1 (en)
AU (1) AU2004285503A1 (en)
BR (1) BRPI0415935A (en)
CA (1) CA2543696A1 (en)
CY (1) CY1110176T1 (en)
DE (1) DE602004018363D1 (en)
DK (1) DK1677827T3 (en)
ES (1) ES2319775T3 (en)
IL (1) IL175211A0 (en)
MX (1) MXPA06004723A (en)
NO (1) NO20062428L (en)
PL (1) PL1677827T3 (en)
PT (1) PT1677827E (en)
RU (1) RU2006118359A (en)
SI (1) SI1677827T1 (en)
WO (1) WO2005042020A2 (en)
ZA (1) ZA200603863B (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (en) * 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
PE20050374A1 (en) 2003-09-05 2005-05-30 Vertex Pharma SERINE PROTEASE INHIBITORS, IN PARTICULAR HCV PROTEASE NS3-NS4A
AR049297A1 (en) * 2004-06-08 2006-07-12 Vertex Pharma A PHARMACEUTICAL COMPOSITION AND SOLID DISPERSIONS OF VX-950 (INHIBITOR OF THE HCV PROTEASE NS3 / 4A) AND OBTAINING PROCESS
WO2006130553A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
RU2441020C2 (en) * 2005-08-02 2012-01-27 Вертекс Фармасьютикалз Инкорпорейтед Serine protease inhibitors
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (en) * 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP1991229A2 (en) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CN101460166B (en) 2006-03-06 2014-11-19 Abbvie公司 Compositions and methods of use of ritonavir for treating hcv
EP2194039A1 (en) 2006-03-16 2010-06-09 Vertex Pharmceuticals Incorporated Process for preparing optically enriched compounds
AU2007226983A1 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
EP1998759A2 (en) * 2006-03-23 2008-12-10 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
WO2007133865A2 (en) 2006-04-11 2007-11-22 Novartis Ag Hcv/hiv inhibitors an their uses
WO2007149382A2 (en) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in treating hepatitis
AR061838A1 (en) * 2006-07-07 2008-09-24 Gilead Sciences Inc THERAPEUTIC PHARMACOCINETIC PROPERTIES MODULATORS
CA2669938C (en) * 2006-11-15 2016-01-05 Abbott Laboratories Solid pharmaceutical dosage formulations
CN101903392A (en) * 2007-02-27 2010-12-01 弗特克斯药品有限公司 Inhibitors of serine proteases
BRPI0807907A2 (en) * 2007-02-27 2017-05-16 Vertex Pharma cocrystals and pharmaceutical compositions comprising them.
KR20100040896A (en) * 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 Modulators of pharmacokinetic properties of therapeutics
TW200922933A (en) * 2007-08-30 2009-06-01 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
US20090082366A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telaprevir
AU2008309589B2 (en) 2007-10-10 2012-07-05 Novartis Ag Spiropyrrolidines and their use against HCV and HIV infection
EP2444070A1 (en) * 2008-02-28 2012-04-25 Abbott Laboratories Tablets
SG172353A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
MX2011006332A (en) * 2008-12-23 2011-06-27 Abbott Lab Anti-viral compounds.
US8314135B2 (en) * 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
EP2393359A4 (en) * 2009-02-09 2012-10-03 Enanta Pharm Inc Linked dibenzimidazole derivatives
US8242156B2 (en) * 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010099432A2 (en) * 2009-02-26 2010-09-02 The Johns Hopkins University Recognition of cyp2e1 epitopes
US8101643B2 (en) * 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
CN102459165B (en) * 2009-04-15 2015-09-02 Abbvie公司 Antiviral compound
PE20120638A1 (en) * 2009-04-25 2012-05-26 Hoffmann La Roche PHARMACEUTICAL COMBINATIONS INCLUDING DANOPREVIR OR A SALT OF THE SAME, AND RITONAVIR
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
CA2737601C (en) * 2009-06-11 2014-10-21 Abbott Laboratories Anti-viral compounds
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2010148006A1 (en) * 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2475256A4 (en) * 2009-09-11 2013-06-05 Enanta Pharm Inc Hepatitis c virus inhibitors
US8703938B2 (en) * 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) * 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) * 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) * 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8653070B2 (en) * 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CN102843909A (en) 2010-01-25 2012-12-26 埃南塔制药公司 Hepatitis c virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8178531B2 (en) * 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
CN102858157A (en) * 2010-03-04 2013-01-02 埃南塔制药公司 Combination pharmaceutical agents as inhibitors of hcv replication
JP5872539B2 (en) 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー Purine nucleoside phosphoramidate
WO2011127350A1 (en) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc Hepatitis c virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012021704A1 (en) * 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
JP5909495B2 (en) 2010-10-08 2016-04-26 ノバルティス アーゲー Vitamin E formulation of sulfamide NS3 inhibitor
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2012158861A2 (en) 2011-05-18 2012-11-22 Enanta Pharmaceuticals, Inc. Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
RU2013155713A (en) 2011-07-06 2015-08-20 Профибрикс Бв COMPOSITIONS FOR TREATMENT OF THE RAS
SMT201800087T1 (en) 2011-09-16 2018-03-08 Gilead Pharmasset Llc Methods for treating hcv
US9180193B2 (en) * 2011-10-10 2015-11-10 Hoffmann-La Roche Inc. Antiviral compounds
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AU2013201406B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
CA2873529C (en) * 2012-05-18 2020-08-18 Replicor Inc. Oligonucleotide chelate complex-polypeptide compositions and methods
US20140024613A1 (en) * 2012-06-27 2014-01-23 Abbvie Inc. Methods for Treating HCV
EA029081B9 (en) 2013-01-31 2018-09-28 Джилид Фармассет Ллс Combination formulation of two antiviral compounds
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
JP7068827B2 (en) * 2015-06-30 2022-05-17 アイガー グループ インターナショナル インコーポレイテッド Use of chloroquine and cremisol compounds to treat inflammatory and cancerous conditions
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
KR20220035365A (en) * 2019-07-18 2022-03-22 엔요 파마 How to reduce the side effects of interferon
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779653B1 (en) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med USE OF PROTEASOME MODULATING COMPOUNDS IN THERAPY
SV2003000617A (en) * 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
BR0210357A (en) * 2001-06-11 2004-06-29 Shire Biochem Inc Compound and methods for the treatment or prevention of flavivirus infections
EP1613620A1 (en) * 2003-04-11 2006-01-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CN102020700A (en) * 2003-07-18 2011-04-20 沃泰克斯药物股份有限公司 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
PE20050374A1 (en) * 2003-09-05 2005-05-30 Vertex Pharma SERINE PROTEASE INHIBITORS, IN PARTICULAR HCV PROTEASE NS3-NS4A
EP1692157B1 (en) * 2003-10-10 2013-04-17 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
AR055395A1 (en) * 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS

Also Published As

Publication number Publication date
CA2543696A1 (en) 2005-05-12
EP1677827B1 (en) 2008-12-10
KR20060120162A (en) 2006-11-24
EP1677827A2 (en) 2006-07-12
DK1677827T3 (en) 2009-03-30
CN1893978A (en) 2007-01-10
US20120114604A1 (en) 2012-05-10
PL1677827T3 (en) 2009-06-30
DE602004018363D1 (en) 2009-01-22
SI1677827T1 (en) 2009-06-30
NO20062428L (en) 2006-05-29
US20060003942A1 (en) 2006-01-05
MXPA06004723A (en) 2006-07-05
JP2007509950A (en) 2007-04-19
BRPI0415935A (en) 2007-01-02
IL175211A0 (en) 2006-09-05
WO2005042020A2 (en) 2005-05-12
PT1677827E (en) 2009-03-13
ZA200603863B (en) 2007-11-28
US20100015090A1 (en) 2010-01-21
AU2004285503A1 (en) 2005-05-12
ES2319775T3 (en) 2009-05-12
ATE416789T1 (en) 2008-12-15
WO2005042020A3 (en) 2005-06-23
RU2006118359A (en) 2007-12-10

Similar Documents

Publication Publication Date Title
CY1110176T1 (en) Combinations For HCV Therapy
PT1268519E (en) PROTEASE SERINE INHIBITORS, PARTICULARLY PROTEASE NS3 HEPATITIS C VIRUS
BRPI0410456B8 (en) hepatitis c inhibitor compounds, pharmaceutical composition, use thereof, as well as an article of manufacture
SG159385A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
PL1987038T3 (en) Hcv ns5b inhibitors
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
MX2009009176A (en) Inhibitors of serine proteases.
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
ATE469155T1 (en) CYCLOPROPYL-FUSIONED INDOLEBENZAZEPINE HCV NS5B INHIBITORS
TNSN08033A1 (en) Hcv ns3 protease inhibitors
SG155967A1 (en) Hcv ns3-ns4a protease inhibition
TW200728317A (en) Macrocylic inhibitors of hepatitis C virus
UY27798A1 (en) INHIBITORS OF THE RNA-DEPENDENT RNA POLYMERASE OF THE HEPATITS C VIRUS AND COMPOSITIONS AND TREATMENTS USING THEM.
UA95990C2 (en) Hcv ns3 protease inhibitors